Vaccination against diphtheria has reduced the mortality and morbidity of diphtheria dramatically, however diphtheria is still a significant child health problem in countries with poor routine childhood immunization coverage. In countries endemic for diphtheria, the disease occurs mostly as sporadic cases or in small outbreaks. Diphtheria is fatal in 5 - 10% of cases, with a higher mortality rate in young children. Treatment involves administering diphtheria antitoxin to neutralize the effects of the toxin, as well as antibiotics to kill the bacteria.

Diphtheria vaccine is a bacterial toxoid, ie. a toxin whose toxicity has been inactivated. The vaccine is normally given in combination with other vaccines, including tetanus and pertussis (e.g. DTwP/DTaP, pentavalent vaccine). For adolescents and adults the diphtheria toxoid is frequently combined with tetanus toxoid in lower concentration (Td vaccine).

WHO recommends a 3-dose primary vaccination series with diphtheria containing vaccine followed by 3 booster doses. The primary series should begin as early as 6-week of age with subsequent doses given with a minimum interval of 4 weeks between doses. The 3 booster doses should preferably be given during the second year of life (12-23 months), at 4-7 years and at 9-15 years of age. Ideally, there should be at least 4 years between booster doses.

WHO Health Topic

Prequalified vaccines

Other WHO links

WHO partner links